Evaluation of Endocrine Related Adverse Effects of Non-Endocrine Targeted Pharmaceuticals in Cellular Systems
CONCLUSION: Present data suggest that all tested pharmaceuticals may have potential endocrine disrupting effect, which should be considered when used in pregnancy.PMID:36843259 | DOI:10.2174/1871530323666230224145624 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - February 27, 2023 Category: Drugs & Pharmacology Authors: Bita Entezari Deniz Bozdag Hande Gurer-Orhan Source Type: research
Evaluation of Endocrine Related Adverse Effects of Non-Endocrine Targeted Pharmaceuticals in Cellular Systems
CONCLUSION: Present data suggest that all tested pharmaceuticals may have potential endocrine disrupting effect, which should be considered when used in pregnancy.PMID:36843259 | DOI:10.2174/1871530323666230224145624 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - February 27, 2023 Category: Endocrinology Authors: Bita Entezari Deniz Bozdag Hande Gurer-Orhan Source Type: research
Evaluation of Endocrine Related Adverse Effects of Non-Endocrine Targeted Pharmaceuticals in Cellular Systems
CONCLUSION: Present data suggest that all tested pharmaceuticals may have potential endocrine disrupting effect, which should be considered when used in pregnancy.PMID:36843259 | DOI:10.2174/1871530323666230224145624 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - February 27, 2023 Category: Drugs & Pharmacology Authors: Bita Entezari Deniz Bozdag Hande Gurer-Orhan Source Type: research
Evaluation of Endocrine Related Adverse Effects of Non-Endocrine Targeted Pharmaceuticals in Cellular Systems
CONCLUSION: Present data suggest that all tested pharmaceuticals may have potential endocrine disrupting effect, which should be considered when used in pregnancy.PMID:36843259 | DOI:10.2174/1871530323666230224145624 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - February 27, 2023 Category: Endocrinology Authors: Bita Entezari Deniz Bozdag Hande Gurer-Orhan Source Type: research
Pantoprazole Induced Stevens-Johnson Syndrome: A case-report
CONCLUSION: This case highlights the possible occurrence of hypersensitivity reactions due to the use of a PPI, which is a widely used medication and a generally well-tolerated drug.PMID:36823997 | DOI:10.2174/1574886318666230224092818 (Source: Current Drug Safety)
Source: Current Drug Safety - February 24, 2023 Category: Drugs & Pharmacology Authors: Mouna Daldoul Ons Charfi Emna Bouattour Houda Hammami-Ghorbe Ahmed Zaiem Samy Fenniche Ghozlane Lakhoua Sihem El Aidli Source Type: research
Pantoprazole Induced Stevens-Johnson Syndrome: A case-report
CONCLUSION: This case highlights the possible occurrence of hypersensitivity reactions due to the use of a PPI, which is a widely used medication and a generally well-tolerated drug.PMID:36823997 | DOI:10.2174/1574886318666230224092818 (Source: Current Drug Safety)
Source: Current Drug Safety - February 24, 2023 Category: Drugs & Pharmacology Authors: Mouna Daldoul Ons Charfi Emna Bouattour Houda Hammami-Ghorbe Ahmed Zaiem Samy Fenniche Ghozlane Lakhoua Sihem El Aidli Source Type: research
Pantoprazole Induced Stevens-Johnson Syndrome: A case-report
CONCLUSION: This case highlights the possible occurrence of hypersensitivity reactions due to the use of a PPI, which is a widely used medication and a generally well-tolerated drug.PMID:36823997 | DOI:10.2174/1574886318666230224092818 (Source: Current Drug Safety)
Source: Current Drug Safety - February 24, 2023 Category: Drugs & Pharmacology Authors: Mouna Daldoul Ons Charfi Emna Bouattour Houda Hammami-Ghorbe Ahmed Zaiem Samy Fenniche Ghozlane Lakhoua Sihem El Aidli Source Type: research
14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial
Conclusion: In this trial, we found that 14-day HT had a similar eradication rate to BQT but fewer side effects, which may be better for elderly patients. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - February 1, 2023 Category: Drugs & Pharmacology Source Type: research
Nanocracker capable of simultaneously reversing both P-glycoprotein and tumor microenvironment
J Control Release. 2023 Jan 9:S0168-3659(22)00875-6. doi: 10.1016/j.jconrel.2022.12.061. Online ahead of print.ABSTRACTHere, we describe a multidrug-resistant nanocracker (MDRC) that can treat multi-drug resistant (MDR) cancer by recognizing the acidic microenvironment and inhibiting two mechanisms of MDR such as P-glycoprotein (P-gp) and vacuolar-type ATPase (V-ATPase). MDRC is a liposome formulation co-loading pantoprazole (PZ) and paclitaxel (PTX). PZ acts as a chemosensitizer that enhances the MDR cancer treatment effect of PTX by disrupting the pH gradient and inhibiting P-gp. MDRC-encapsulated PZ and PTX have differe...
Source: Cancer Control - January 12, 2023 Category: Cancer & Oncology Authors: Taebum Lee Kyoung Sub Kim Kun Na Source Type: research
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use
CONCLUSION: Higher-quality data is needed to better understand PPI-associated risks of the adverse effects listed above. Until then, clinicians may consider greater vigilance with PPI use; however, the data does not demonstrate a need for wide adoption of de-escalation strategies solely out of safety concerns.PMID:36629265 | DOI:10.1093/ajhp/zxad009 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 11, 2023 Category: Drugs & Pharmacology Authors: Kristina M Thurber Ashley O Otto Shawna L Stricker Source Type: research
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use
CONCLUSION: Higher-quality data is needed to better understand PPI-associated risks of the adverse effects listed above. Until then, clinicians may consider greater vigilance with PPI use; however, the data does not demonstrate a need for wide adoption of de-escalation strategies solely out of safety concerns.PMID:36629265 | DOI:10.1093/ajhp/zxad009 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 11, 2023 Category: Drugs & Pharmacology Authors: Kristina M Thurber Ashley O Otto Shawna L Stricker Source Type: research
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use
CONCLUSION: Higher-quality data is needed to better understand PPI-associated risks of the adverse effects listed above. Until then, clinicians may consider greater vigilance with PPI use; however, the data does not demonstrate a need for wide adoption of de-escalation strategies solely out of safety concerns.PMID:36629265 | DOI:10.1093/ajhp/zxad009 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 11, 2023 Category: Drugs & Pharmacology Authors: Kristina M Thurber Ashley O Otto Shawna L Stricker Source Type: research
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use
CONCLUSION: Higher-quality data is needed to better understand PPI-associated risks of the adverse effects listed above. Until then, clinicians may consider greater vigilance with PPI use; however, the data does not demonstrate a need for wide adoption of de-escalation strategies solely out of safety concerns.PMID:36629265 | DOI:10.1093/ajhp/zxad009 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 11, 2023 Category: Drugs & Pharmacology Authors: Kristina M Thurber Ashley O Otto Shawna L Stricker Source Type: research
The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients
ConclusionIn ICU patients, the association between PPI prescription and increased risk of QT interval prolongation was independent of known QT-prolonging factors; pantoprazole and lansoprazole had a higher risk compared with omeprazole. The combination of PPIs and other QT-prolonging drugs should be avoided. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 10, 2023 Category: Cardiology Source Type: research
